MARKET

ATAI

ATAI

Atai Life Sciences B.V.
NASDAQ
1.610
+0.240
+17.52%
After Hours: 1.600 -0.01 -0.62% 19:55 11/15 EST
OPEN
1.500
PREV CLOSE
1.370
HIGH
1.650
LOW
1.430
VOLUME
6.17M
TURNOVER
--
52 WEEK HIGH
2.850
52 WEEK LOW
1.025
MARKET CAP
270.16M
P/E (TTM)
-2.0175
1D
5D
1M
3M
1Y
5Y
1D
ATAI Life Sciences: Strategic Advancements and Strong Financials Underpin Buy Rating
TipRanks · 21h ago
Vaccine Stocks Slide, Psychedelic Stocks Surge After RFK Jr. HHS Nomination
Barchart · 1d ago
RFK and the 'MAHA Trade': Vaccine makers down, psychedelic shares up
Seeking Alpha · 2d ago
Rising High: Cannabis firms report quarterly earnings
TipRanks · 2d ago
Atai Life Sciences Advances Psychedelic Treatments in Q3 2024
TipRanks · 3d ago
TD Cowen Sticks to Its Buy Rating for ATAI Life Sciences (ATAI)
TipRanks · 3d ago
AI And Psychedelics: A Marriage Made In Heaven For Mental Health Care?
Benzinga · 3d ago
Atai Q3 Report: Strong Cash Position, Clinical Pipeline Growth
Benzinga · 4d ago
More
About ATAI
ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. The Company engages in developing various treatments that focuses on various mental health disorders. The Company's therapeutic lead compound include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder.

Webull offers ATAI Life Sciences NV stock information, including NASDAQ: ATAI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATAI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATAI stock methods without spending real money on the virtual paper trading platform.